A close-up photograph of a person's face and arm. The person's hand is resting on their shoulder, which has a large, red, scaly patch of psoriasis. The background is a soft, out-of-focus light gray.

# The COSENTYX<sup>®</sup> SensoReady<sup>®</sup> pen

COSENTYX<sup>®</sup> (secukinumab) is indicated for the treatment of:<sup>1</sup>

- Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
- Severe plaque psoriasis in pediatric patients 12 to less than 18 years of age who are candidates for systemic therapy or phototherapy and have a body weight  $\geq 50$  kg
- Adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX<sup>®</sup> can be used alone or in combination with methotrexate
- Adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy

 **Cosentyx<sup>®</sup>**  
secukinumab

# The COSENTYX® SensoReady® pen: Designed with patients in mind


COSENTYX® is administered by syringe or via the SensoReady® pen with autoinject functionality



Designed to be easy to use  
for people living with arthritis



## Dosing information for plaque psoriasis



Please see the Product Monograph for complete dosing and administration information for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

## Important safety information

Consult the Product Monograph at [www.novartis.ca/CosentyxMonograph](http://www.novartis.ca/CosentyxMonograph) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-800-363-8883.

**Reference: 1.** COSENTYX® Product Monograph. Novartis Pharmaceuticals Canada Inc. January 20, 2021.



Novartis Pharmaceuticals Canada Inc.  
Dorval, Québec H9S 1A9  
[www.novartis.ca](http://www.novartis.ca)  
☎ 514.631.6775 ☎ 514.631.1867

COSENTYX and SensoReady are registered trademarks.  
Product Monograph available on request.  
Printed in Canada [CODE]  
© Novartis Pharmaceuticals Canada Inc. May 2021.

